All In Biotech

Drug Trial Radar · NCT07260851

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "DWJ1622" and Co-administration of "DWC202313" and "DWC202314" in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Jan 30, 2026

Study completion May 30, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fasting conditions.

Conditions

  • Healthy Volunteers

Interventions

  • DWJ1622Drug

    DWJ1622 (single oral dose) is administered in accordance with the study protocol.

  • DWC202313, DWC202314Drug

    DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
  2. AUClastTime frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H Plus YANGJI Hospital

    Seoul, Gwanak-gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.